MedTrace Logo

Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis

NCT01063803 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 266

Last updated 2016-04-11

No results posted yet for this study

Summary

This open-label extension study will allow subjects who have completed either the 3242K1-2000-WW or 3242K1-2001-JA study to receive up to an additional 48 weeks of ATN-103 treatment and will provide data on the long-term safety and tolerability of ATN-103 in subjects with rheumatoid arthritis.

Conditions

Interventions

DRUG

ATN-103

A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)

DRUG

ATN-103

A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)

Sponsors & Collaborators

  • Ablynx, a Sanofi company

    lead INDUSTRY

Principal Investigators

  • Medical Director, MD · Ablynx NV

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States
  • Canada
  • Hungary
  • Japan
  • Russia
  • Serbia
  • South Africa
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01063803 on ClinicalTrials.gov